Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Article
Nature , 1267-1270 (30 June 2005) | doi:10.1038/nature03669;
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellow in Immunology
- The Scripps Research Institute
- N Torrey Pines Rd, San Diego, CA, USA
University Full-Professor (W3, Tenure Track)
- University of Münster
- Munster 48149 Germany
Dynamics of chronic myeloid leukaemia
The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain. Can imatinib eradicate leukaemic stem cells?
&
Abstract
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
